For the year ending 2025-12-31, TOI had -$16,104K decrease in cash & cash equivalents over the period. -$27,787K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -60,606 |
| Depreciation and amortization | 6,944 |
| Amortization of debt issuance costs and debt discount | 8,380 |
| Write-off of assets from clinical trials segment | 2,398 |
| Share-based compensation | 4,551 |
| Change in fair value of liability classified warrants | 247 |
| Change in fair value of liability classified conversion option derivatives | -12,206 |
| Unrealized (gain) loss on investments | 0 |
| Accretion of discount on investment securities | 0 |
| Deferred taxes | -32 |
| Loss on disposal of property and equipment | 0 |
| Accounts receivable | 12,308 |
| Inventories | 6,836 |
| Other receivables | 274 |
| Prepaid expenses | -2,033 |
| Other assets | 17 |
| Accrued expenses and other current liabilities | -448 |
| Accounts payable | 19,638 |
| Change in operating leases | -452 |
| Other non-current liabilities | -11 |
| Net cash and cash equivalents used in operating activities | -24,587 |
| Purchases of property and equipment | 3,200 |
| Proceeds from asset disposition | 126 |
| Sales of marketable securities/investments | 0 |
| Net cash and cash equivalents provided by (used in) investing activities | -3,074 |
| Proceeds from private placement, net of offering costs | 15,359 |
| Proceeds from at-the-market offering, net of offering costs | 13,841 |
| Proceeds from employee stock purchase plan | 151 |
| Payments made for financing of insurance payments | 991 |
| Payment of deferred consideration liability for acquisition | 50 |
| Principal payments on long-term debt | 20,000 |
| Principal payments on financing leases | 37 |
| Common stock issued for warrants exercised | 517 |
| Common stock issued for options exercised | 2,767 |
| Net cash and cash equivalents provided by (used in) financing activities | 11,557 |
| Net (decrease) increase in cash and cash equivalents | -16,104 |
| Cash and cash equivalents at beginning of period | 49,669 |
| Cash and cash equivalents at end of period | 33,565 |
Oncology Institute, Inc. (TOI)
Oncology Institute, Inc. (TOI)